OPA1 and acute myeloid leukemia: However, the only pharmacological inhibitor of mitochondrial fusion currently available is the small compound OPA1 inhibitor MYLS22 [38], which significantly reduced mitochondrial length and decreased ROS content in AML cells (Fig. 5A, B and Supplementary Fig. S5B).